

DAFTAR PUSTAKA

- Adli, F. K. (2021). Diabetes Melitus Gestasional : Diagnosis dan Faktor Risiko. *Jurnal Medika Utama*, 03(01), 1545–1551.
- American Association of Clinical Endocrinologists (AACE). (2023). Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. Endocrine Practice*, 29(4), 377–400.
- American Diabetes Association. (2024). Standards of Care in Diabetes—2024. Diabetes Care*, 47(Suppl 1): S1–S292. <https://doi.org/10.2337/dc24-S001>
- Bailey, C.J., et al. (2020). *Safety and tolerability of DPP-4 inhibitors: Review of gastrointestinal adverse events. Diabetes Therapy*, 11(1), 25–45.
- BPJS Kesehatan. (2022). Kebijakan Pengadaan Obat dan Alat Kesehatan dalam Sistem JKN. Jakarta: BPJS Kesehatan.
- BPOM. (2019). Farmakovigilans (Keamanan Obat): Panduan Deteksi dan Pelaporan Efek Samping Obat Untuk Tenaga Kesehatan. Pusat Farmakovigilans Nasional, 1–26.
- Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2021). Goodman & Gilman's: *The Pharmacological Basis of Therapeutics* (13th ed.). McGraw-Hill Education.
- Camilleri, M., Bharucha, A. E., & Farrugia, G. (2021). *Diabetic Gastroparesis: Pathophysiology, Clinical Presentation, and Management. Gastroenterology*, 160(4), 1235–1249.
- Centers for Disease Control and Prevention. National Diabetes Statistics Report 2022, Table 6.*
- Chang AM et al. *The Effect of Aging on Glucose Regulation in Healthy Adults. J Clin Endocrinol Metab.* 2006;91(3):935–943.
- Davies MJ, et al. (2022). *Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care*, 45(11): 2753–2786. <https://doi.org/10.2337/dci22-0034>
- Decroli, E. (2019). Diabetes Melitus Tipe 2. In Pusat Penerbitan Bagian Ilmu Penyakit dalam Fakultas Kedokteran Universitas Andalas. Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas Padang, 2019. <https://doi.org/10.2169/naika.96.899>
- Desi, Eka Rini, W. N., & Halim, R. (2018). Determinan Diabetes Melitus Tipe 2 Di Kelurahan Talang Bakung Kota Jambi. *Jurnal Kesmas Jambi*, 2(1), 50–58. <https://doi.org/10.22437/jkmj.v2i1.6539>

- Dinkes, K. T. (2021). Laporan kinerja instansi pemerintah Kabupaten Tasikmalaya 2020. 1–173.
- EMA. (2022). *European Public Assessment Report (EPAR) on Vildagliptin*. <https://www.ema.europa.eu>
- EMA. (2022). Vildagliptin: *European Public Assessment Report – Summary of Product Characteristics*.
- European Medicines Agency (EMA). (2021). *Assessment Report: Vildagliptin and Risk of Liver Injury*. EMA/COM/23413/2021.
- Gale, E.A.M. (2019). *Sex and gender differences in diabetes risk and management*. *Diabetologia*, 62(3), 453–461.
- Gallwitz, B. (2021). *Clinical Use of DPP-4 Inhibitors*. *Diabetes Care*, 44(Suppl 1), S21–S28. <https://doi.org/10.2337/dc21-S004>
- Giugliano, D., Longo, M., Signoriello, S., Maiorino, M. I., Solerte, B., Chiodini, P., & Esposito, K. (2022). *The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs*. *Cardiovascular Diabetology*, 21(1), 1–10. <https://doi.org/10.1186/s12933-022-01474-z>
- Horowitz, M., & Fraser, R. (2020). *Disordered gastric motor function in diabetes mellitus: Gastroparesis and related disorders*. *The Lancet Gastroenterology & Hepatology*, 5(6), 543–555.
- Huang, J., Jia, Y., Sun, S., & Meng, L. (2020). *Adverse event profiles of dipeptidyl peptidase-4 inhibitors: Data mining of the public version of the FDA adverse event reporting system*. *BMC Pharmacology and Toxicology*, 21(1). <https://doi.org/10.1186/s40360-020-00447-w>
- IDF. (2021). IDF Diabetes Atlas 10th Edition. In *International Diabetes Federation*. <https://diabetesatlas.org/atlas/tenth-edition/>
- IDF. (2024). *What About Diabetes*. <https://idf.org/about-diabetes/what-is-diabetes/>
- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al. (2022). *Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD*. *Diabetes Care*, 45(11), 2753–2786. <https://doi.org/10.2337/dci22-0034>
- Kanie, T., Mizuno, A., Yoneoka, D., Ww, T., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., & Jsw, K. (2020). *with cardiovascular disease : a network meta-analysis (Protocol)*. *Cochrane Database of Systematic Reviews*, 12(123). <https://doi.org/10.1002/14651858.CD013650.pub2>. Copyright
- Kemenkes, R. (2020). Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/603/2020 Tentang Pedoman Nasional Pelayanan

Kedokteran Tata Laksana Diabetes Melitus Tipe 2 Dewasa.
<https://doi.org/10.1088/1751-8113/44/8/085201>

- Kementerian Kesehatan RI. (2018). Laporan Nasional Riset Kesehatan Dasar (Riskesdas).
- Kementerian Kesehatan RI. (2023). Formularium Nasional Edisi 2023. Jakarta: Kemenkes RI.
- Kim, Y.S., et al. (2021). *Effectiveness and tolerability of vildagliptin in Asian populations: Results from the VICTORY study*. *Int J Clin Pract*, 75(2): e13732.
- Kusnadi, G., Murbawani, E. A., & Fitranti, D. Y. (2017). Faktor risiko diabetes melitus tipe 2 pada petani dan buruh. *Journal of Nutrition College*, 6(2), 138. <https://doi.org/10.14710/jnc.v6i2.16905>
- Lee, H., et al. (2021). *Post-Marketing Surveillance of DPP-4 Inhibitors: Analysis of Adverse Event Reports*. *Frontiers in Pharmacology*, 12, 678453.
- Lestari, Zulkarnain, Sijid, & Aisyah, S. (2021). Diabetes Melitus: Review Etiologi, Patofisiologi, Gejala, Penyebab, Cara Pemeriksaan, Cara Pengobatan dan Cara Pencegahan. *UIN Alauddin Makassar*, 1(2), 237–241. <http://journal.uin-alauddin.ac.id/index.php/psb>
- Libman, I., Haynes, A., Lyons, S., Pradeep, P., Rwagasor, E., Tung, J. Y. ling, Jefferies, C. A., Oram, R. A., Dabelea, D., & Craig, M. E. (2022). *ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents*. *Pediatric Diabetes*, 23(8), 1160–1174. <https://doi.org/10.1111/pedi.13454>
- Lin, J., Thompson, T. J., Cheng, Y. J., Zhuo, X., Zhang, P., Gregg, E., & Rolka, D. B. (2018). *Projection of the future diabetes burden in the United States through 2060*. *Population Health Metrics*, 16(1), 1–9. <https://doi.org/10.1186/s12963-018-0166-4>
- Milita, F., Handayani, S., & Setiaji, B. (2021). Kejadian Diabetes Mellitus Tipe II pada Lanjut Usia di Indonesia (Analisis Riskesdas 2018). *Jurnal Kedokteran Dan Kesehatan*, 17(1), 9. <https://doi.org/10.24853/jkk.17.1.9-20>
- Muhammad, A. A. (2018). Resistensi Insulin Dan Disfungsi Sekresi Insulin Sebagai Faktor Penyebab Diabetes Melitus Tipe 2. *Jurnal Kesehatan Masyarakat*, 8(2), 174–178. <http://jurnal.unismuhpalu.ac.id/index.php/PJKM>
- Octavia, D. R., Yuliandhari, R., & Pangestu, D. P. (2024). Algoritme Naranjo sebagai Metode Identifikasi Dini Efek Samping Obat pada Pasien Tuberkulosis Resisten Obat di RS Muhammadiyah Lamongan. *Lambung Farmasi: Jurnal Ilmu Kefarmasian*, 5(2), 142. <https://doi.org/10.31764/lf.v5i2.19659>

- PERKENI. (2021). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. 46. www.ginasthma.org.
- Prasetyo, A., & Nugroho, B. (2021). Analisis Ketersediaan Obat Diabetes Modern pada RSUD dan Swasta di Jawa Barat. *Jurnal Kefarmasian Indonesia*, 8(2), 102–110.
- Putra, I. W. A., & Berawi, K. N. (2015). Empat Pilar Penatalaksanaan Pasien Diabetes Mellitus Tipe 2. *Majority*, 4(9), 8–12.
- Rosenstock, J., et al. (2019). *Safety and Efficacy of Vildagliptin: A 5-Year Review. Diabetic Medicine*, 36(4), 462–470.
- Rukmana, D., et al. (2023). Analisis Kausalitas Reaksi Obat Merugikan di RSUD Wilayah Priangan Timur. *Jurnal Manajemen Pelayanan Kesehatan*, 26(1), 18–25.
- Saputri, S. W., Nugraha, A., Pratama, W., & Holidah, D. (2016). Studi Pengobatan Diabetes Melitus Tipe 2 dengan Komplikasi Hipertensi di Instalasi Rawat Jalan RSUD dr. H. Koesnadi Bondowoso Periode Tahun 2014 (Study of Treatment of Type 2 Diabetes Mellitus with Hypertension in Outpatient Departement of dr. H. Koesnadi. *E-Jurnal Pustaka Kesehatan*, 4(3), 479–483.
- Scheen, A.J. (2020). *Clinical safety of vildagliptin. Expert Opinion on Drug Safety*, 19(4), 409–421.
- Scheen, A.J. (2020). *DPP-4 inhibitors and safety: Focus on vildagliptin. Expert Opin Drug Saf*, 19(4), 511–520.
- Scheen, A.J. (2020). *DPP-4 inhibitors in the management of type 2 diabetes: Clinical pharmacology and safety. Expert Opinion on Pharmacotherapy*, 21(16), 1967–1981.
- Scheen, A.J. (2020). *DPP-4 inhibitors in type 2 diabetes: Focus on vildagliptin. Expert Opin Drug Metab Toxicol*, 16(6): 517–528.
- Scheen, A.J. (2020). *Hepatic Safety of Vildagliptin: Analysis of Clinical Trials and Postmarketing Data. Expert Opinion on Drug Safety*, 19(2), 145–153.
- Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016). *The time is right for a new classification system for diabetes: Rationale and implications of the β -cell-centric classification schema. Diabetes Care*, 39(2), 179–186. <https://doi.org/10.2337/dc15-1585>
- Sudargo, T. dkk., (2018). *Pola Makan Dan Obesitas*. Book, Ugm Press.
- Suryanti s, Dkk. (2021). “Hubungan Gaya Hidup Dengan Pola Makan Dengan Kejadian Diabetes Mellitus Di Rumah Sakit Bhayangkara Kota Makassar”., *Jurnal Promotif Preventif. Fakultas Kesehatan Masyarakat, Universitas Panca Sakti. Makassar. Vo.4 No.1*.

- Stottlemeyer, B. A., McDermott, M. C., Minogue, M. R., Gray, M. P., Boyce, R. D., & Kane-Gill, S. L. (2023). *Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study*. *Therapeutic Advances in Drug Safety*, 14, 1–14. <https://doi.org/10.1177/20420986231181334>
- Team Medical Mini Notes. (2019). *Basic Pharmacology & Drug Notes*. MMN Publishing
- U.S. Food and Drug Administration. (2023). “What is an Adverse Event?” <https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program>
- Valoka, A. D. W. I., & Reinaldi, H. (2017). Dampak Negatif Makanan Cepat Saji Terhadap Kesehatan Tubuh Manusia Di Kota Bandung Melalui Still Life Photography.
- WHO–UMC. (2022). *The Use of the WHO-UMC system for standardised case causality assessment*. Uppsala Monitoring Centre.
- WHO. (2020). *Safety of medicines – adverse drug reactions*. 1–3. https://www.who.int/docs/default-source/medicines/safety-of-medicines--adverse-drug-reactions-jun18.pdf?sfvrsn=4fc4f40_2
- WHO. (2024). Diabetes, *World Health Organization*. https://www.who.int/health-topics/diabetes#tab=tab_1
- Widyastuti, A., et al. (2022). Evaluasi Pola Penggunaan Obat Diabetes di Fasilitas Kesehatan Daerah. *Jurnal Farmasi Klinis Indonesia*, 11(1), 33–41.
- World Health Organization (WHO)*. (2021). *Global Pharmacovigilance Report on DPP-4 inhibitors*.
- World Health Organization (WHO)*. (2021). *Global Report on Diabetes and Obesity*. Geneva: WHO Press.
- Wulan, A.S., & Prasetya, B. (2020). Studi Farmakovigilans Reaksi Obat Merugikan di Rumah Sakit Pendidikan. *Jurnal Farmasi Sains dan Praktis*, 6(2), 84–90.
- Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C. Z., Wan, J. Y., & Yuan, C. S. (2024). *Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis*. *Bmj*. <https://doi.org/10.1136/bmj-2023-076410>
- Yohanes, D. C. (2020). Penghambat Sodium-Glucose Cotransporter-2. *Acta Pharmaciae Indonesia : Acta Pharm Indo*, 8(1), 26. <https://doi.org/10.20884/1.api.2020.8.1.2450>